Contraceptive vaccines

Expert Opinion on Biological Therapy

Volumn 3, Issue 5, 2003, Pages 829-841

  McLaughlin, Eileen A ^a   Holland, Michael K ^b   Aitken, R J ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Contraception; Human chorionic gonadotropin; Oocytes; Spermatozoa; Zona pellucida

Indexed keywords

BACTERIAL PROTEIN; CHOLERA TOXIN B SUBUNIT; CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN ANTIBODY; CONTRACEPTIVE VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DIPHTHERIA TETANUS TOXOID; ENTEROTOXIN; ENTEROTOXIN B; FERTILIN; FOLLITROPIN; GLYCOPROTEIN GP 120; GONADORELIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS 1 PROTEIN; HUMAN IMMUNOGLOBULIN; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE ISOENZYME X; MALE CONTRACEPTIVE AGENT; PH 17 ANTIGEN; PH 20 ANTIGEN; PH 30 ANTIGEN; QS 21; SP56 ANTIGEN; SPERM ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZONA PELLUCIDA PROTEIN;

ANTIBODY TITER; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; EMBRYO TRANSFER; EPIDIDYMITIS; FERTILITY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCONTRACEPTION; LIBIDO DISORDER; MENOPAUSE; MUCOSAL IMMUNITY; NIDATION; NONHUMAN; OOCYTE; OVARY FOLLICLE; OVARY FOLLICLE DEVELOPMENT; PREGNANCY TERMINATION; RELIABILITY; REVIEW; SPERMATOGENESIS; SPERMATOZOON MIGRATION; TESTIS DISEASE; ZONA PELLUCIDA;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS; CARRIER PROTEINS; FEMALE; HORMONES; HUMANS; IMMUNITY, MUCOSAL; MALE; OVARY; SPERMATOZOA; VACCINES, CONTRACEPTIVE; VACCINES, DNA;

BACTERIA (MICROORGANISMS); HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0042671195     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.3.5.829     Document Type: Review

References (113)

1. BAIRD DT, GLASIER AF: Science, medicine, and the future. Contraception. Br. Med. J. (1999) 319:969-972.
2. GUPTA SK: The immunology of reproduction: update. Immunol. Today (1998) 19:433-434.
3. ALEXANDER NJ, BIALY G: Contraceptive vaccine development. Reprod. Fertil. Dev. (1994) 6:273-280.
4. BEDFORD JM: Sperm/egg interaction: the specificity of human spermatozoa. Anat Rec. (1977) 188:477-488.
5. SZCZEPANSKA M, SKRZYPCZAK J, KAMIENICZNA M, KURPISZ M: Antizona and antisperm antibodies in women with endometriosis and/or infertility. Fertil. Steril. (2001) 75:97-105
6. HOVAV Y, ALMAGOR M, BENBENISHTI D, MARGALIOTH EJ, KAFKA I, YAFFE H: Immunity to zona pellucida in women with low response to ovarian stimulation, in unexplained infertility and after multiple IVF attempts. Hum. Reprod. (1994) 9:643-645.
7. WASSARMAN PM: Zona pellucida glycoproteins. Ann. Rev. Biochem. (1988) 57:415-442.
8. RANKIN T, FAMILARI M, LEE E et al.: Mice homozygous for an insertional mutation in the Zp3 gene lack a zona pellucida and are infertile. Development (1996) 122:2903-2910.
9. RANKIN T, TALBOT P, LEE E, DEAN J: Abnormal zonae pellucidae in mice lacking ZP1 result in early embryonic loss. Development (1999) 126:3847-3855.
10. RANKIN TL, O'BRIEN M, LEE E, WIGGLESWORTH K, EPPIG J, DEAN J: Defective zonae pellucidae in Zp2-null mice disrupt folliculogenesis, fertility and development. Development (2001) 128:1119-11126.
11. PRASAD SV, WILKINS B, SKINNER SM, DUNBAR BS: Evaluating zona pellucida structure and function using antibodies to rabbit 55 kDa ZP protein: expressed in baculovirus expression system. Mol. Reprod. Dev. (1996) 43:519-529.
12. GOVIND CK, GAHLAY GK, CHOUDHURY S, GUPTA SK: Purified and refolded recombinant bonnet monkey (Macaca radiata) zona pellucida glycoprotein-B expressed in Escherichia coli binds to spermatozoa. Biol. Reprod. (2001) 64:1147-1152.
13. KIRKPATRICK JF, TURNER JW JR, LIU IK, FAYRER-HOSKEN R: Applications of pig zona pellucida immunocontraception to wildlife fertility control. J. Reprod. Fertil. Suppl. (1996) 50:183-189.
14. PATERSON M, WILSON MR, MORRIS KD, VAN DUIN M, AITKEN RJ: Evaluation of the contraceptive potential of recombinant ZP3 and human ZP3 peptides in a primate model - their safety and efficacy. Am. J. Reprod. Immunol. (1998) 40:198-209.
15. HENDERSON CJ, BRAUDE P, AITKEN RJ: Polyclonal antibodies to a 32 kDa deglycosylated polypeptide from the porcine zona pellucida will prevent human gamete interaction in vitro. Gamete Res. (1987) 18:251-265.
16. HENDERSON CJ, HULME MJ, AITKEN RJ: Analysis of the biological properties of antibodies raised against intact and deglycosylated porcine zonae pellucidae. Gamete Res. (1987) 16:323-341.
17. TURNER JW JR, LIU IK, FLANAGAN DR, BYNUM KS, RUTBERG AT: Porcine zona pellucida (PZP) immunocontraception of wild horses (Equus caballus) in Nevada: a 10 year study. Reproduction (2002) 60 (Suppl.):177-186. Recent example of contraceptive vaccines targeting the ZP finding application in the control of feral animal populations.
18. JACKSON RJ, MAGUIRE DJ, HINDS LA, RAMSHAW IA: Infertility in mice induced by a recombinant ectromelia virus expressing mouse zona pellucida glycoprotein 3. Biol. Reprod. (1998) 58:152-159.
19. AITKEN RJ, PATERSON M, VAN DUIN M: The potential of the zona pellucida as a target for immunocontraception. Am. J. Reprod. Immunol. (1996) 35:175-180.
20. AITKEN RJ: Immunocontraceptive vaccines for human use. J. Reprod Immunol. (2002) 57:273-287. Recent review of the status of contraceptive vaccines targeting the ZP, sperm surface and implanting embryo.
21. KERR PJ, JACKSON RJ, ROBINSON AJ et al.: Infertility in female rabbits (Oryctolagus cuniculus) alloimmunized with the rabbit zona pellucida protein ZPB either as a purified recombinant protein or expressed by recombinant myxoma virus. Biol. Reprod. (1999) 61:606-613.
22. JONES GR, SACCO AG, SUBRAMANIAN MG et al.: Histology of ovaries of female rabbits immunized with deglycosylated zona pellucida macromolecules of pigs. J. Reprod. Fertil. (1992) 95:513-525.
23. PATERSON M, KOOTHAN PT, MORRIS KD et al.: Analysis of the contraceptive potential of antibodies against native and deglycosylated porcine ZP3 in vivo and in vitro. Biol. Reprod (1992) 46:523-534. This paper clearly demonstrates that the ovarian pathology associated with the induction of active immunity against ZP antigens is not dependent on glycosylation, but is triggered by antibodies directed against the peptide core of these molecules.
24. GARZA KM, TUNG KS: Frequency of molecular mimicry among T cell peptides as the basis for autoimmune disease and autoantibody induction. J. Immunol. (1995) 155:5444-5448.
25. LOU Y, ANG J, THAI H, MCELVEEN F, TUNG KS: A zona pellucida 3 peptide vaccine induces antibodies and reversible infertility without ovarian pathology. J. Immunol. (1995) 155:2715-27120.
26. PATERSON M, JENNINGS Z, WILSON MR, AITKEN RJ: The contraceptive potential of ZP3 and ZP3 peptides in a primate model. J. Reprod. Immunol. (2002) 53:99-107.
27. BAGAVANT H, FUSI FM, BAISCH J, KURTH B, DAVID CS, TUNG KS: Immunogenicity and contraceptive potential of a human zona pellucida 3 peptide vaccine. Biol. Reprod. (1997) 56:764-770.
28. HULL MGR, GLAZENER CMA, KELLY NJ et al.: Population study of causes, treatment and outcome of infertility. Br. Med. J. (1985) 291:1693-1697.
29. BASKIN MJ: Temporary sterilization by the injection of human spermatozoa. A preliminary report. Am. J. Obst. Gyn. (1932) 24:892-897. Historically important paper demonstrating that human semen contains antigens with contraceptive potential
30. AITKEN RJ, PARSLOW JM, HARGREAVE TB, HENDRY WF: Influence of antisperm antibodies on human sperm function. Br. J. Urol. (1988) 62:367-373.
31. GUPTA I, DHAWAN S, GOEL GD, SAHA K: Low fertility rate in vasovasostomized males and its possible immunologic mechanism. Int. J. Fertil. (1975) 20:183-191.
32. O'RAND MG: Inhibition of fertility and sperm-zona binding by antiserum to the rabbit sperm membrane autoantigen RSA-1. Biol. Reprod (1981) 25:621-628.
33. PRIMAKOFF P, LATHROP W, WOOLMAN L, COWAN A, MYLES DG: Fully effective contraception in male and female guinea pigs immunized with the sperm protein PH-20. Nature (1988) 35:543-546.
34. PRIMAKOFF P, HYATT H, TREDICK-KLINE J: Identification and purification of a sperm surface protein with a potential role in sperm-egg membrane fusion. J. Cell Biol. (1987) 104:141-149.
35. KUAMAYA PTP, VAN BUSKIRK AM, GOLDBERG E, PIERCE SK: Design and immunological properties of topographic immunogenic determinants of a protein antigen (LDH-C4) as vaccines. J. Biol. Chem. (1992) 267:6338-6346.
36. HERR JC, FLICKINGER CJ, HOMYK M, KLOTZ K, JOHN E: Biochemical and morphological characterisation of the intra-acrosomal antigen SP-10 from human sperm. Biol. Reprod (1990) 42:181-193.
37. BLEIL JD, WASSARMAN PM: Identification of a ZP3-binding protein on acrosome-intact mouse sperm by photoaffinity crosslinking. Proc. Natl. Acad. Sci. USA (1990) 87:5563-5567.
38. NAZ RK, WOLF DP: Antibodies to sperm-specific human FA-1 inhibit in vitro fertilization in rhesus monkeys: development of a simian model for testing of anti-FA-1 contraceptive vaccine. J. Reprod. Immunol. (1994) 27:111-121.
39. LEFEVRE A, MARTIN RUIZ C, CHOKOMIAN S, DUQUENNE C, FINAZ C: Characterization and isolation of SOB2, a human sperm protein with a potential role in oocyte membrane binding. Mol. Hum. Reprod (1997) 3:507-516.
40. DIEKMAN AB, NORTON EJ, KLOTZ KL, WESTBROOK VA, HERR JC: Evidence for a unique N-linked glycan associated with human infertility on sperm CD52: a candidate contraceptive vaccinogen. Immunol. Rev. (1999) 171:203-211.
41. BABA D, KASHIWABARA S, HONDA A et al.: Mouse sperm lacking cell surface hyaluronidase PH-20 can pass through the layer of cumulus cells and fertilize the egg. J. Biol. Chem. (2002) 277:30310-30314. Important paper indicating that PH20 is not essential for fertilisation and, therefore, not a candidate for contraceptive vaccine development.
42. TUNG KS, PRIMAKOFF P, WOOLMAN-GAMER L, MYLES DG: Mechanism of infertility in male guinea pigs immunized with sperm PH-20. Biol. Reprod. (1997) 56:1133-1141.
43. HOLLAND MK, ANDREWS J, CLARKE H, WALTON C, HINDS LA: Selection of antigens for use in a virus-vectored immunocontraceptive vaccine: PH-20 as a case study. Reprod. Fertil. Dev. (1997) 9:117-124.
44. POMERING M, JONES RC, HOLLAND MK, BLAKE AE, BEAGLEY KWP: Restricted entry of IgG into male and female rabbit reproductive ducts following immunization with recombinant rabbit PH-20. Am. J. Reprod. Immunol. (2002) 47:174-182.
45. DENG X, HE Y, MARTIN-DELEON PA: Mouse Spaml (PH-20): evidence for its expression in the epididymis and for a new category of spermatogenic-expressed genes. J. Androl. (2000) 21:822-832.
46. ZHANG H, MARTIN-DELEON PA: Mouse Epididymal Spam1 (PH-20) is released in the luminal fluid with its lipid anchor. J. Androl. (2003) 24:51-58.
47. ZHANG H, MARTIN-DELEON PA: Mouse Spam1 (PH-20) is a multifunctional protein: Evidence for its expression in the Female reproductive tract. Biol. Reprod. (2003) (e-Pub ahead of print).
48. O'HERN PA, BAMBRA CS, ISAHAKIA M, GOLDBERG E: Reversible contraception in female baboons immunized with a synthetic epitope of sperm-specific lactate dehydrogenase. Biol. Reprod. (1995) 52:331-339.
49. O'HERN PA, LIANG ZG, BAMBRA CS, GOLDBERG E: Colinear synthesis of an antigen-specific B-cell epitope with a 'promiscuous' tetanus toxin T-cell epitope: a synthetic peptide immunocontraceptive. Vaccine (1997) 15:1761-1766.
50. GUPTA GS, MALHOTRA R: Autoimmune-like activity of sperm specific LDH: a pathophysiological and electron microscopic study of atrophied testis and epididymis. Indian J. Biochem. Biophys. (1994) 31:480-485.
51. GOLDBERG E, VANDEBERG JL, MAHONY MC, DONCEL GF: Immune response of male baboons to testis-specific LDH-C(4). Contraception (2001) 64:93-98.
52. HERR J: Update on sperm antigen-based contraceptive vaccines. Immunol. Allergy Clin North Am. (2002) 22:503-527.
53. CHENG A, LE T, PALACIOS M et al.: Sperm-egg recognition in the mouse: characterization of sp56, a sperm protein having specific affinity for ZP3. J. Cell Biol. (1994) 125:867-878.
54. HARDY CM, MOBBS KJ: Expression of recombinant mouse sperm protein sp56 and assessment of its potential for use as an antigen in an immunocontraceptive vaccine. Mol. Reprod Dev. (1999) 52:216-224.
55. KIM KS, CHA MC, GERTON GL: Mouse sperm protein sp56 is a component of the acrosomal matrix. Biol. Reprod. (2001) 64:36-43.
56. COHEN N, WASSARMAN PM: Association of egg zona pellucida glycoprotein mZP3 with sperm protein sp56 during fertilization in mice. Int. J. Dev. Biol. (2001) 45:569-576.
57. BLOBEL CP, WOLFSBERG TG, TURCK CW, MYLES DG, PRIMAKOFF P, WHITE JM: A potential fusion peptide and an integrin ligand domain in a protein active in sperm-egg fusion. Nature (1992) 356:248-252.
58. WOLFSBERG TG, STRAIGHT PD, GERENA RL et al.: ADAM, a widely distributed and developmentally regulated gene family encoding membrane proteins with a disintegrin and metalloprotease domain. Dev. Biol. (1995) 169:378-383.
59. FRAYNE J, JURY JA, BARKER HL, HALL L: Rat MDC family of proteins: sequence analysis, tissue distribution, and expression in prepubertal and adult rat testis. Mol. Reprod. Dev. (1997) 48:159-167.
60. MYLES DG, KIMMEL LH, BLOBEL CP, WHITE JM, PRIMAKOFF P: Identification of a binding site in the disintegrin domain of fertilin required for sperm-egg fusion. Proc. Natl. Acad. Sci. USA (1994) 91:4195-4198.
61. EVANS JP, SCHULTZ RM, KOPF GS: Roles of the disintegrin domains of mouse fertilins alpha and beta in fertilization. Biol. Reprod. (1998) 59:145-152.
62. RAMARAO CS, MYLES DG, WHITE JM, PRIMAKOFF P: Initial evaluation of fertilin as an immunocontraceptive antigen and molecular cloning of the cynomolgus monkey fertilin beta subunit. Mol. Reprod. Dev. (1996) 43:70-75.
63. HARDY CM, CLARKE HG, NIXON B, GRIGG JA, HINDS LA, HOLLAND MK: Examination of the immunocontraceptive potential of recombinant rabbit fertilin subunits in rabbit. Biol. Reprod. (1997) 57:879-886.
64. HE ZY, BRAKEBUSCH C, FASSLER R, KREIDBERG JA, PRIMAKOFF P, MYLES DG: None of the integrins known to be present on the mouse egg or to be ADAM receptors are essential for sperm-egg binding and fusion. Dev. Biol. (2003) 254:226-237. Recent demonstration that neither integrins on the surface of the oocyte, nor presumably the sperm ADAM proteins that target them, are involved in sperm-oocyte fusion. These molecules, therefore, are unlikely to be effective targets for contraceptive vaccines.
65. MCLAUGHLIN EA, FRAYNE J, BLOOMERG G, HALL L: Do fertilin beta and cyritestin play a major role in mammalian sperm-oolemma interactions? A critical re-evaluation of the use of peptide mimics in identifying specific oocyte recognition proteins. Mol. Hum. Reprod. (2001) 7:313-317.
66. JURY JA, FRAYNE J, HALL L: The human fertilin alpha gene is non-functional: implications for its proposed role in fertilization. Biochem. J. (1997) 321:577-581.
67. TALWAR GP: Fertility regulating and immunotherapeutic vaccines reaching human trials stage. Hum. Reprod. Update (1997) 3:301-310. Review of the status of contraceptive vaccines targeting hCG.
68. SINGH M, DAS SK, SURI S, SINGH O, TALWAR GP: Regain of fertility and normality of progeny born during below protective threshold antibody titers in women immunized with the HSD-hCG vaccine. Am. J. Reprod. Immunol. (1998) 39:395-398.
69. MANDOKHOT A, PAL R, NAGPAL S, CHAUHAN VS, AHLAWAT S, SINGH O: Humoral hyporesponsiveness to a conjugate contraceptive vaccine and its bypass by diverse carriers using permissible adjuvant. Clin. Exp. Immunol. (2000) 122:101-108.
70. MUKHOPADHYAY A: Reversible protection of disulfide bonds followed by oxidative folding render recombinant hCG beta highly immunogenic. Vaccine (2000) 18:1802-1810.
71. GUPTA A, CHANDRASEKHAR S, PAL R, AHLAWAT S, SINGH O: High expression of human chorionic gonadotrophin beta-subunit using a synthetic vaccinia virus promoter. J. Mol. Endocrinol. (2001) 26:281-287
72. CHIESA MD, MARTENSEN PM, SIMMONS C et al.: Refocusing of B-cell responses following a single amino acid substitution in an antigen. Immunology (2001) 103:172-178. An example of how careful modification of a peptide antigen can redirect the immune response to achieve an improvement in target specificity.
73. SHAH S, RAGHUPATHY R, SINGH O, TALWAR GP, SODHI A et al.: Prior immunity to a carrier enhances antibody responses to hCG in recipients of an hCG-carrier conjugate vaccine. Vaccine (1999) 17:3116-3123.
74. MOUDGAL NR, MURTHY GS, PRASANNA KUMAR KM et al.: Responsiveness of human male volunteers to immunization with ovine follicle stimulating hormone vaccine: results of a pilot study. Hum. Reprod. (1997) 12:457-463.
75. ZENG W, GHOSH S, LAU YF, BROWN LE, JACKSON DC: Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J. Immunol. (2002) 169:4905-4912.
76. DELVES PJ, LUND T, ROITT IM: Antifertility vaccines. Trends Immunol. (2002) 23:213-219.
77. BRANDTZAEG P: The oral immune system under normal and pathological conditions. Pathol. Res. Pract. (1985) 179:619-621.
78. CONLEY ME, DELACROIX DL: Intravascular and mucosal immunoglobulin A: two separate but related systems of immune defence? Ann. Intern. Med. (1987) 106:892-899.
79. MESTECKY J, LUE C, RUSSELL MW et al.: Selective transport of IgA. Cellular and molecular aspects. Gastroenterol. Clin. North Am. (1991) 20:441-471.
80. KUTTEH WH, MESTECKY J: The concept of mucosal immunology. In: Reproductive Immunology Bronson RA, Alexander NJ, Anderson DJ, Branch DW, Kutteh WH (Eds), Blackwell Science Ltd, Oxford (1996):28-51. A thorough review of mucosal immunity.
81. EGGERT-KRUS EW, BOCKEM-HELLWIG S, DOLL A, ROHR G, TILGEN W, RUNNEBAUM B: Antisperm antibodies in cervical mucus in an unselected subfertile population. Hum. Reprod. (1993) 8:1025-1031.
82. ROSENTHAL KL, GALLICHAN WS: Challenges for vaccination against sexually-transmitted diseases: induction and long-term maintenance of mucosal immune responses in the female genital tract. Semin. Immunol. (1997) 9:303-314.
83. RUSSELL MW, MOLDOVEANU Z, WHITE PL, SIBERT GJ, MESTECKY J, MICHALEK SM: Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the Cholera toxin B subunic. Infect. Immun. (1996) 64:1272-1283. Paper demonstrating the feasibility of inducing generalised IgA antibody responses in the mucosal immune system through the intranasal administration of antigen.
84. RASK C, FREDRIKSSON M, LINDBLAD M, CZERKINSKY C, HOLMGREN J: Mucosal and systemic antibody responses after peroral or intranasal immunization: effects of conjugation to enterotoxin B subunits and/or of co-administration with free toxin as adjuvant. APMIS (2000) 108:178-186.
85. FRANKLIN RD, KUTTEH WH: Characterization of immunoglobulins and cytokines in human cervical mucus: influence of exogenous and endogenous hormones. J. Reprod. Immunol. (1999) 42:93-106.
86. MCGHEE JR, MESTECKY J, ELSON CO, KIYONO H: Regulation of IgA synthesis and immune response by T cells and interleukins. J. Clin. Immunol. (1989) 9:175-199.
87. PRABHALA RH, WIRA CR: Cytokine regulation of the mucosal immune system: in vivo stimulation by interferon-gamma of secretory component and immunoglobulin A in uterine secretions and proliferation of lymphocytes from spleen. Endocrinology (1991) 129:2915-2923.
88. PRABHALA RH, WIRA CR: Influence of estrous cycle and estradiol on mitogenic responses of splenic T- and B-lymphocytes. Adv. Exp. Med. Biol. (1995) 371A:379-381.
89. KUTTEH WH, MOLDOVEANU Z, MESTECKY J et al.: Mucosal immunity in the female reproductive tract: correlation of immunoglobulins, cytokines, and reproductive hormones in human cervical mucus around the time of ovulation. AIDS Res. Hum. Retroviruses (1998) 14(Suppl. 1):S51-S55.
90. EDWARDS RP, KUYKENDALL K, CROWLEY-NOWICK P, PARTRIDGE EE, SHINGLETON HM, MESTECKY J: T lymphocytes infiltrating advanced grades of cervical neoplasia. CD8-positive cells are recruited to invasion. Cancer (1995) 76:1411-1415.
91. GLENN GM, SCHARTON-KERSTEN T, VASSELL R, MALLETT CP, HALE TL, ALVING CR: Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J. Immunol. (1998) 161:3211-3214.
92. GLENN GM, SCHARTON-KERSTEN T, VASSELL R, MATYAS GR, ALVING CR: Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect. Immun. (1999) 67:1100-1106.
93. GOCKEL CM, BAO S, BEAGLEY KW: Transcutaneous immunization induces mucosal and systemic immunity: a potent method for targeting immunity to the female reproductive tract. Mol. Immunol. (2000) 37:537-544.
94. GLENN GM, TAYLOR DN, LI X, FRANKEL S, MONTEMARANO A, ALVING CR: Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat. Med (2000) 6:1403-1406.
95. ULANOVA M, TARKOWSKI A, HAHN-ZORIC M, HANSON LA: The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect. Immun. (2001) 69:1151-1159.
96. GREER CE, PETRACCA R, BUONAMASSA DT et al.: The comparison of the effect of LTR72 and MF59 adjuvants on mouse humoral response to intranasal immunisation with human papillomavirus Type 6b (HPV-6b) virus-like particles. Vaccine (2000) 19:1008-1012.
97. EVANS TG, MCELRATH MJ, MATTHEWS T et al.: QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans. Vaccine (2001) 19:2080-2091.
98. KIM SK, RAGUPATHI G, CAPPELLO S, KAGAN E, LIVINGSTON PO: Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates. Vaccine (2000) 19:530-537.
99. FREIDAG BL, MELTON GB, COLLINS F et al.: CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium boris BCG vaccination in mice challenged with M. tuberculosis. Infect. Immun. (2000) 68:2948-2953.
100. BUCHANAN RM, BRILES DE, ARULANANDAM BP, WESTERINK MA, RAEDER RH, METZGER DW: IL-12-mediated increases in protection elicited by pneumococcal and meningococcal conjugate vaccines. Vaccine (2001) 19:2020-2028.
101. HANCOCK GE, HEERS KM, SMITH JD: QS-21 synergizes with recombinant interleukin-12 to create a potent adjuvant formulation for the fusion protein of respiratory syncytial virus. Viral Immunol. (2000) 13:503-509.
102. SHEDLOCK DJ, WEINER DB: DNA vaccination: antigen presentation and the induction of immunity. J. Leukoc. Biol. (2000) 68:793-806. Review of DNA vaccination strategy.
103. DONNELLY JJ, ULMER JB: DNA vaccines for viral diseases. Braz. J. Med. Biol. Res. (1999) 32:215-222.
104. RAMSHAW IA, RAMSAY AJ: The prime-boost strategy: exciting prospects for improved vaccination. Immunol. Today (2000) 21:163-165.
105. DELIYANNIS G, BOYLE JS, BRADY JL, BROWN LE, LEW AM: A fusion DNA vaccine that targets antigen-presenting cells increases protection from viral challenge. Proc. Natl. Acad. Sci. USA (2000) 97:6676-6680.
106. HUANG TH, WU PY, LEE CN et al.: Enhanced antitumor immunity by fusion of CTLA-4 to a self tumor antigen. Blood (2000) 96:3663-3670.
107. LEW AM, BRADY BJ, BOYLE BJ: Site-directed immune responses in DNA vaccines encoding ligand-antigen fusions. Vaccine (2000) 18:1681-1685.
108. RODRIGUEZ F, ZHANG J, WHITTON JL: DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J. Virol. (1997) 71:8497-8503.
109. CHEN Y, LIU Z, YANG Y, CHEN YZ, PENG JP: Infertility in mice induced by the rhesus monkey chorionic gonadotropin beta-subunit glycoprotein (rmCGbeta) using DNA immunization. Mol Cell Biochem. (2002) 231:89-96.
110. XIANG RL, ZHOU F, YANG Y, PENG JP: Construction of the plasmid pCMV4-rZPC' DNA vaccine and analysis of its contraceptive potential. Biol. Reprod (2003) 68:1518-24.
111. COONROD SA, WRIGHT PW, HERR JC: Oolemmal proteomics. J. Reprod. Immunol. (2002) 53:55-65.
112. KASS E, PANICALI DL, MAZZARA G, SCHLOM J, GREINER JW: Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res. (2001) 61:206-214.
113. JACKSON RJ, RAMSAYA J, CHRISTENSEN CD, BEATON S, HALL DF, RAMSHAW IA: Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J. Virol. (2001) 75:1205-1210.